Davita Inc vs Victoria's Secret & Co — how do they compare? Davita Inc trades at $179.24 (market cap $11.29B), while Victoria's Secret & Co trades at $82.5 (market cap $6.91B). The key difference: Davita Inc is the larger of the two by market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Victoria's Secret & Co for 34 Days on average.
| DVA | VSXY | |
|---|---|---|
Market Cap | $11.29B | $6.91B |
Volume | 582,204 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $99.97 |
52-Week Low | $103.87 | $28.25 |
Typical Hold Time | 113 Days | 34 Days |
Enterprise Value | $24.01B | $9.29B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Victoria's Secret (VSXY) trades at $85.79, up 0.83% with a bullish technical signal and strong earnings beat history. The stock shows robust profitability with 45.27% ROE and 39.57% gross margins, though net margins remain modest at 5.47%. Recent news highlights fashion show expansion and global growth initiatives, with institutional buying supporting positive sentiment. The current price sits near the consensus target of $86.80, with support at $85 and resistance at $87.
VSXY presents a compelling growth story with accelerating fundamentals and analyst support, though rich valuation at 19.33 P/E and competitive retail pressures warrant caution. The 2026 outlook improvement and consistent earnings beats provide upside potential, while margin pressures and consumer spending volatility represent key risks for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →